Rheumatoid Factor: A Critical Biomarker in Rheumatic Diseases

Department of Biochemistry, Jimma University, Ethiopia

*Corresponding Author:

Sarah Deson
Department of Biochemistry, Jimma University, Ethiopia
E-mail: sarah79de@yahoo.com

Received: 01-Jun-2024, Manuscript No. fmijcr-24-145770; Editor assigned: 03- Jun-2024, Pre-QC No. fmijcr-24-145770 (PQ); Reviewed: 17-Jun-2024, QC No. fmijcr-24-145770; Revised: 22- Jun- 2024, Manuscript No. fmijcr-24-145770 (R); Published: 28- Jun-2024, DOI: 10.37532/1758-4272.2024.19(6).205-207

Abstract

Rheumatoid factor (RF) is an important biomarker used in the diagnosis and management of rheumatic diseases, particularly rheumatoid arthritis (RA). It is an autoantibody, meaning it is an antibody produced by the immune system that mistakenly targets the body’s own tissues. Specifically, RF is directed against the Fc region of immunoglobulin G (IgG), forming immune complexes that contribute to the inflammatory processes seen in RA and other autoimmune conditions. The presence of RF in a patient’s blood has significant diagnostic and prognostic implications, making it a cornerstone in the clinical assessment of rheumatic diseases.

Introduction

The discovery of rheumatoid factor dates back to the 1940s, when it was first identified in patients with rheumatoid arthritis. Since then, RF has become one of the most widely used serological tests in rheumatology. While its presence is strongly associated with RA, RF is not exclusively found in this condition. Elevated levels of RF can also be seen in other autoimmune diseases, such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome, as well as in chronic infections and certain malignancies. Despite this lack of specificity, the test remains valuable because a high RF titter, especially when combined with clinical symptoms, strongly suggests the diagnosis of RA [1-3].

Methodology

The role of rheumatoid factor in the pathogenesis of rheumatoid arthritis is still not fully understood, but it is believed to contribute to the inflammatory process that characterizes the disease. In RA, the formation of RF-IgG immune complexes can activate the complement system, a part of the immune response that enhances inflammation. This activation leads to the recruitment of inflammatory cells to the joints, where they release cytokines and enzymes that cause synovial inflammation, joint swelling, and eventually cartilage and bone destruction. The presence of RF is associated with more severe disease, including a higher likelihood of joint damage and extra-articular manifestations such as rheumatoid nodules and vasculitis [4-6].

Testing for rheumatoid factor is a standard procedure in the diagnostic workup of suspected rheumatoid arthritis. The test is typically performed using an enzyme-linked immunosorbent assay (ELISA) or nephelometry, which measure the concentration of RF in the blood. A positive RF test is generally defined by a titter above a certain threshold, often 1:80 or higher, though this can vary depending on the laboratory. It is important to note that while a positive RF test supports the diagnosis of RA, it is not definitive on its own. Approximately 20-30% of RA patients may have a negative RF test, a condition known as seronegative RA. Conversely, RF can be present in healthy individuals, particularly the elderly, as well as in patients with other autoimmune or chronic diseases [7, 8].

The prognostic significance of rheumatoid factor in rheumatoid arthritis is well established. High RF levels are associated with more aggressive disease and a poorer prognosis. Patients with high RF titers are more likely to develop joint erosions, severe functional impairment, and extra-articular complications. As a result, the presence of RF often prompts clinicians to initiate more aggressive treatment early in the disease course to prevent long-term joint damage and disability. However, the interpretation of RF levels should always be considered in the context of the patient’s clinical presentation and other laboratory findings, such as anti-citrullinated protein antibodies (ACPAs), which are more specific for RA and provide additional prognostic information [9,10].

Conclusion

In conclusion, rheumatoid factor is a key biomarker in the diagnosis and management of rheumatic diseases, particularly rheumatoid arthritis. Its discovery has greatly enhanced our ability to diagnose RA early and stratify patients based on their risk of severe disease. Despite its limitations, such as its presence in other conditions and in a subset of healthy individuals, RF remains an invaluable tool in rheumatology. Its role in the pathogenesis of RA highlights the complex interplay between autoantibodies and the immune system in driving chronic inflammation and joint damage. As research continues to uncover more about the underlying mechanisms of rheumatoid factor and its interaction with other biomarkers, our understanding and management of rheumatoid arthritis and other rheumatic diseases will continue to improve, offering hope for better outcomes for patients.

References

1. Thorn, Caroline F. Doxorubicin Pathways: Pharmacodynamics and Adverse Effects. Pharmacogenet Genomics. 21, 440-446 (2011).

Indexed at, Google Scholar, Crossref

2. Brunelli D, Polonelli T, Benini L. Ultra-low energy pest detection for smart agriculture. IEEE Sens J. 1-4 (2020).

Indexed at, Google Scholar

3. Crippen TL, Poole TL.Conjugative transfer of plasmid-located antibiotic resistance genes within the gastrointestinal tract of lesser mealworm larvae,Alphitobius diaperinius(Coleoptera: Tenebrionidae). Foodborne Pathog Dis. 7, 907-915 (2009).

Indexed at, Google Scholar, Crossref

4. Dwyer, Claire. ‘Highway to Heaven’: the creation of a multicultural, religious landscape in suburban Richmond, British Columbia. Soc Cult Geogr. 17, 667-693 (2016).

Indexed at, Google Scholar, Crossref

5. Südfeld S.Post-induction hypotension and early intraoperative hypotension associated with general anaesthesia. Br J Anaesth. 81, 525-530 (2017).

Indexed at, Google Scholar, Crossref

6. Makam AN, Nguyen OK. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. Circulation. 135, 180-195 (2017).

Indexed at, Google Scholar, Crossref

7. Chandalia M, Lutjohann D, von Bergmann K et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med. 342, 1392-1398 (2000).

Indexed at, Google Scholar, Cross ref

8. Gething MJ. Role and regulation of the ER chaperone BiP. Seminars in Cell and Developmental Biology. 10, 465-472 (1999).

Indexed at, Google Scholar, Crossref

9. Schepers E, Meert N, Glorieux G et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 22, 592-596 (2006).

Indexed at, Google Scholar, Crossref

10. Ricci Z, Ronco C, Amico GD et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant. 21, 690-696 (2006).

Indexed at, Google Scholar, Crossref